1. The accumulation of
amyloid beta protein (Abeta) in the brain is a characteristic feature of
Alzheimer's disease (AD). Clinical trials of AD patients with nonsteroidal anti-inflammatory drugs (
NSAIDs) indicate a clinical benefit.
NSAIDs are presumed to act by suppressing inhibiting chronic
inflammation in the brain of AD patients. 2. In the present study, we investigated effects of
S-2474 on Abeta-induced cell death in primary cultures of rat cortical neurons. 3.
S-2474 is a novel
NSAID, which inhibits cyclo-oxygenase-2 (COX-2) and contains the di-tert-butylphenol
antioxidant moiety.
S-2474 significantly prevented neurons from Abeta(25 - 35)- and Abeta(1 - 40)-induced cell death.
S-2474 ameliorated Abeta-induced apoptotic features such as the condensation of
chromatin and the fragmentation of
DNA completely. 4. Prior to cell death, Abeta(25 - 35) generated
prostaglandin D(2) (
PGD(2)) and
free radicals from neurons.
PGD(2) is a product of
cyclo-oxygenase (COX), and caused neuronal cell death. 5.
S-2474 significantly inhibited the Abeta(25 - 35)-induced generation of
PGD(2) and
free radicals. 6. The present cortical cultures contained little non-neuronal cells, indicating that
S-2474 affected neuronal survival directly, but not indirectly via non-neuronal cells. Both an inhibitory effect of COX-2 and an
antioxidant effect might contribute to the
neuroprotective effects of
S-2474. 7. In conclusion,
S-2474 exhibits protective effects against neurotoxicity of Abeta. Furthermore, the present study suggests that
S-2474 may possess therapeutic potential for AD via ameliorating degeneration in neurons as well as suppressing chronic
inflammation in non-neuronal cells.